MBCC 2010 header

The 2 denosumab biosimilars previously received FDA approval for select patients with multiple myeloma, solid tumor bone metastases, and osteoporosis.

A group of clinicians gives study advice on how to best prepare for the medical oncology board exams.

Investigators of the phase 2 PEVOsq trial identify PD-L1 positivity and HPV positivity as predictive biomarkers of response to the pembrolizumab regimen.

Dive into the latest in genitourinary oncology with "Oncology Decoded," featuring discussions on KEYNOTE-564 with RCC.

Final data from the phase 3 ENLIVEN trial demonstrate long-term tumor responses and a consistent safety profile with pexidartinib.

The FDA has waived the need for a botensilimab monotherapy arm in the phase 3 BATTMAN trial evaluating the combination in MSS metastatic colorectal cancer.